Patricia A. Young, MD
University of California, Los Angeles
2014
$
100000
Irving Feintech Family Foundation Career Development Research Grant
Molecular and immunologic correlates of responses to anti-CD 19 chimeric antigen receptor T cell therapy
CD 19 is a protein on the surface of B cells and serves as a potential target in advanced non-Hodgkin lymphomas and leukemias. One experimental treatment has been anti-CD 19 chimeric antigen receptor (CAR) T cells, which uses the patient’s T cells to engineer an anti-CD 19 portion to specifically recognize and kill CD 19-expressing cells. A clinical trial using anti-CD 19 CAR T cells will be implemented at UCLA in the summer of 2014. We plan to: 1) initiate a phase I clinical trial using transfer of engineered T cells, and 2) perform laboratory studies to improve upon and understand the mechanisms of this treatment.
Support the Journey
When you donate to Tower, you’re not supporting a single study. You’re part of an ecosystem that believes the next breakthrough is out there, waiting for someone to believe in it first. Every gift puts resources directly behind the discoveries that would otherwise never see the light of day.